Back
Langerhans cell histiocytosis with central nervous system involvement--complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib.
Journal article

Langerhans cell histiocytosis with central nervous system involvement--complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib.

  • 2011-07-07
Published in:
  • Hematological oncology. - 2012
Adult
Antineoplastic Agents
Benzamides
Benzenesulfonates
Central Nervous System Diseases
Cladribine
Histiocytosis, Langerhans-Cell
Humans
Imatinib Mesylate
Niacinamide
Phenylurea Compounds
Piperazines
Protein Kinase Inhibitors
Pyridines
Pyrimidines
Sorafenib
English Langerhans cell histiocytosis (LCH) is rare in adults, and only a subset of these patients suffers from central nervous system (CNS) involvement. Hence, evidence-based treatment recommendations are lacking. A case of a 20-year-old student with multisystem LCH and extensive CNS involvement is described, who showed a durable response to 2-chlorodeoxyadenosine after prior therapies with the tyrosine kinase inhibitors sorafenib and imatinib. In accordance to the experiences provided by other case series, which are reviewed herein, 2-chlorodeoxyadenosine can be considered an effective and safe option for adult LCH with CNS involvement.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.rero.ch/global/documents/235459
Statistics
Document views: 22 File downloads: